Quality of life should be measured in clinical interventions to support economic evaluations

This commentary is on the original article by Bekkers et al. on pages 1301–1307 of this issue.

Saved in:
Bibliographic Details
Published in:Developmental medicine and child neurology 2020-11, Vol.62 (11), p.1234-1234
Main Author: Shih, Sophy T F
Format: Article
Language:English
Subjects:
Botulinum Toxins, Type A
Cost-Benefit Analysis
Humans
Quality of Life
Sialorrhea
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This commentary is on the original article by Bekkers et al. on pages 1301–1307 of this issue.
ISSN:0012-1622
1469-8749
DOI:10.1111/dmcn.14656